Summary Inherited susceptibility to a wide variety of neoplasias (Li-Fraumeni syndrome), has been shown in studies of one cancer-prone family, to have an intriguing association with an aberrant c-raf-J gene and inheritance of a radioresistant phenotype in their non-cancerous skin fibroblasts. This association together with observations that DNA topoisomerases, when defective, can introduce errors into DNA and that these enzymes are perturbed in vitro by serine/threonine kinases similar to raf encoded proteins, prompted investigation of DNA topoisomerase activity of the family's fibroblasts. Since radioresistance was transferred to murine cells (NIH-3T3) when the aberrant c-raf-1 gene from this family was transfected, we also examined transformants containing this and other oncogenes. V-raflc-myc and EJ-ras transformants were examined, the former because the family's skin fibroblasts also have 3-8-fold elevated myc expression (not apparently relevant to radioresistance) and the latter because ras, like raf, conveys radioresistance. The family members' fibroblasts and the three transfected murine lines, showed a similar perturbation of a spermidine and ATP-dependent DNA catenation activity (typical of DNA topoisomerase II). There was a significant positive correlation (r = 0.93; P = 0.0026) between the degree of activation of topoisomerase II and one measure of radioresistance (the Dq value). Relaxation of DNA supercoiling (topoisomerase I activity and other DNA nicking enzymes) was not abnormal. Cytotoxicity assays and evaluation of the influence of topoisomerase II inhibitors on DNA/protein complex formation, corroborated the existence of a qualitative topoisomerase II defect in the family's cells and transfectants. Although the contention that the qualitative topoisomerase II abnormalities observed here may be associated with malfunction is highly speculative, these findings may be relevant to the mechanism of oncogenesis, not only in this family, but with raf and ras type oncogenes.
implicated in mutation (Overbye et al., 1982; Pommier et al., 1985) , sister chromatid exchanges (Pommier et al., 1985; Dillehay et al., 1987; Renault et al., 1987) , illegitimate recombination (Bae et al., 1988) , chromosome stickiness (Renault et al., 1987; Gaulden et al., 1987) , fragmentation of DNA (Jaxel et al., 1988) and tumour promotion (Kaneko & Horikoshi, 1987) . The breadth of these observations, including mutant studies and recombination assays where no extraneous agents were used (Overbye et al., 1982; Bae et al., 1988) , and the range of perturbing agents eliciting errors, suggests that this is an inherent property of these enzymes, much exacerbated by a variety of perturbations. Second, the type II enzyme is involved in cellular differentiation (Francis et al., 1987b) .
Third, the function of both type I and II topoisomerases is perturbed by oncogene-derived and cellular protein kinases, including tyrosine kinases (Tse-Dinh et al., 1984) and serine/ threonine kinases (Durban et al., 1983; Rottmann et al., 1987) . The hypothetical link that perturbed topoisomerase action provides between oncogene activation, defective differentiation and a tendency to acquire further genetic changes is provocative, since the latter two functional abnormalities are so frequently found together in pre-neoplastic states.
In the cancer family syndrome described by Li and Fraumeni (1969) susceptibility to many types of neoplasia is inherited in a dominant fashion, including: sarcomas, cancers of the breast and other tissues, neurological tumours and both lymphoid and myeloid leukaemias. Many individuals in six generations of a large kindred had more than one primary cancer (Blattner et al., 1979) . Thus the mechanism of oncogenesis (although unlikely to be identical in each pedigree (Little et al., 1987) ) may be relevant to many forms of non-familial neoplasms. Radiation resistance has been demonstrated in the non cancerous skin fibroblasts from family members (Bech-Hansen et al., 1981) , but this finding is not common to all Li-Fraumeni families (Little et al., 1987) . The ostensibly normal non-cancerous radioresistant cells were found to have an apparent activation of the c-raf-1 gene and a 3-8-fold elevation in the expression of c-myc (Chang et al., 1987) . The transfer of either the family's c-raf-J gene, the genes of other serine/threonine kinases or ras, into murine cells conveyed the radioresistant phenotype, but the myc, fes and abl oncogenes failed to do so (Chang et al., 1987; Pirollo et al., 1989; Sklar, 1988) .
There is a potential, albeit speculative, link between mutability, radiosensitivity and perturbed topoisomerase activity. Bacterial mutants lacking a type I topoisomerase gene are hypersensitive to DNA damage but resistant to mutation (Sternglanz et al., 1981; Overbye et al., 1982) . Chromatin structure, particularly, but not exclusively, 'openness', is known to influence mammalian cell DNA repair (Bohr, 1988) . This may account for observations apparently linking topoisomerase activity to repair capacity, despite failure to detect direct involvement in repair in some systems (see below). Since serine-threonine kinases activate topoisomerases (Durban et al., 1983; Rottman et al., 1987) 
Materials and methods

Genealogy
A full genealogy of the family is not included because this is published elsewhere (Blattner et al., 1979) and that of the branch of the family under study was given previously (Chang et al., 1987) .
Cell lines
Nine fibroblast lines were examined. Details of their origins are given elsewhere (Chang et al., 1987; Pirollo et al., 1989) . Five were human lines, from the proband, great uncle and father of the cancer-prone family, an unaffected spouse and an unrelated ataxia-telangiectasia patient (ATSBI, kindly supplied by Dr M. Paterson to Dr E. Chang). Four were murine NIH-3T3 lines: one containing a truncated c-raf-J gene from a family member (Pirollo et al., 1989 ); a line containing both v-raf and c-myc to simulate the co-existing defects in the family's fibroblasts; and a line containing activated ras (EJ). The recipient NIH-3T3 cells were used as a control.
Cell culture Lines were grown in Ham's F12 medium with 0.12% w/v sodium bicarbonate, 0.27% w/v anhydrous glucose (adjusted to pH 7.2), 2 mM L-glutamine, I mM sodium pyruvate, 1000 IU m-l penicillin, 100 ig ml-' streptomycin solution and 10% heat inactivated fetal calf serum (FCS). Experiments were performed on the mouse lines at confluence and 24 h after splitting (sub-confluent with approximately 60-80% coverage of the flask). The human lines were estimated firstly at confluence, at 24 h post splitting (approximately 50-60% coverage), and thirdly 5 days post splitting having been refed 24 h prior to assay (approximately 50-90% coverage).
Topoisomerase assays
The assay exploits the ability of topoisomerase II to catenate (join by strand passing) supercoiled circular DNA (the plasmid pBR322). The supercoiled substrate plasmid is converted to catenanes, relaxed plasmid and a small fraction is linearised in this reaction. Only catenation is relatively specific for topoisomerase II, the relaxation of supercoiling and linearisation cannot be solely attributed to type II enzyme since topoisomerase I and any DNA nicking enzyme (e.g. endonucleases) can perform this reaction. Since no topoisomerase II assay of crude extracts can be assumed to be specific, the characteristics of the catenation reaction were also evaluated (see Results and Figure 2 below).
Trypinised fibroblasts were diluted in 10 ml Ham's F12 and counted using a Coulter FN. They were centrifuged at 400 g for 6 min and the pellet resuspended in RPMI 1640 with 10% FCS at either 1.2 x 106 or 1.2 x 107 cells ml-', depending on the range of extract concentrations to be tested. The cells were recovered by centrifugation at 400 g for 6 min, 200 g4 of the ice cold cytoplasmic lysis mix was added (10 mM Tris P04 pH 6.75, 1 mM 2-mercaptoethanol, 0.1 mM Na2 EDTA, 0.2 mM EGTA, 10% glycerol (v/v), 0.5% Triton X-100 (v/v) 0.5% Nonidet P-40 (v/v), 1 mM phenylmethylsulphonylfluoride (PMSF), 1 mM dithiothreitol (DTT), 10 mM epsilon aminocaproic acid), left on ice for 5 min, centrifuged at 1,000 g for 8 min and the supernatant reserved on ice (cytoplasmic extract).
The pellet was washed (10 mM Tris HCl pH 7.4, 10 mM NaCl, 1.5 mM MgCI2, 1 mM PMSF, 1 mM DTT), recentrifuged at 1,000 g for 8 min, the supernatant discarded and the pellet dissolved in 25 j1 of nuclear lysis solution (10 mM Tris HCI pH 7.4, 10 mM NaCl, 1.5 mM MgCl2, 1 mM PMSF, 1 mM DTT and 1 MNaCl), then left to stand for 30 min. Polyethylene glycol 6000 (BDH) dissolved in nuclear wash solution was added to a final concentration of 18% and the resulting solution left for a further 15 min, then centriged at 9,000 g for 15 min and the supernatant reserved on ice as the nuclear extract. The final nuclear NaCl concentration was 0.25 M.
Serial dilutions of extracts were made in the appropriate lysis buffer with a highest concentration equivalent to 3 x 104 murine cells, 3 x 105 human cells in the cytoplasmic extract and fourfold higher concentrations for the nuclear extracts were mixed with 5 1 of the reaction mixture (20 mM Tris HCI pH 8.1, 10 mM MgCl2, 20 mM KCI, 0.5 mm Na3 EDTA, 30 jig ml-' bovine serum albumin, 1 mM DTT, 15% glycerol (v/v), 1O mM spermidine, 1O mM ATP and 20 iLgml1' pBR 322 (BCL, supercoiled form) and incubated for 1 h at 33°C. The amount of extract used is expressed as the equivalent number of cells. Captothecin, the lactone form (Sigma), 10-2 M stock in dimethylsulphoxide or appropriate diluent control was added where indicated. In selected experiments spermidine and ATP were omitted from the reaction mixture. The reactions were stopped by adding 2.5 p1 (0.1% SDS, 15 mM EDTA) and 2.5 p1l orange G. The products were electrophoresed through 1% agarose gels with 1 fig ml-' ethidium bromide in tris borate EDTA buffer pH 8.3 for 1 h at 3 V cm-'. The various toplogical forms (catenanes, relaxed, linearised, supercoiled) were measured by scanning densitometry.
Cytotoxicity assays Human fibroblasts growing in log phase were seeded at 2 x I03 cells 100 l-' in 96-well microtitre plates (Nunc). This low cell density was chosen to preclude the possibility of controls achieving confluence while survivors of inhibition can continue to grow. They were incubated for 48 h at 37°C and 5% CO2 in the presence of the DNA topoisomerase II inhibitory agents, diluted in tissue culture medium (100 1), VP16-213, VM26 (both kind gifts of Bristol-Myers Inc., Syracuse, NY, USA), mAMSA (NSC 249992 provided by the Drug Synthesis and Chemistry Branch, NCI) and the less inhibitory analogue of the latter oAMSA (NSC 156306) as well as the DNA topoisomerase I inhibitor camptothecin (Sigma). We also assessed Adriamycin (Farmitalia), which although it inhibits topoisomerase II has additional mechanisms of cytotoxicity including free radical generation (Young et al., 1981) . Cytosine arabinoside (Upjohn) and thioguanine (Sigma), neither of which inhibit topoisomerase II were also examined. All the drugs were freshly dissolved at 10-2 M in appropriate solvents, which were used as diluent controls: the epipodophyllotoxins and amsidine derivatives in DMSO (BDH Spectrosol grade), the thioguanine in 0.1 N NaOH and the rest in water. The dose range tested was 10-9 to IO-5M. After 48 h, cell numbers were estimated using essentially the method of Finlay et al. (1984) using methylene blue staining to assess total cell mass. Robust regression analysis using least absolute deviation (with a robust constant of 1.0) was performed using a proprietary computer algorithm (NCSS copyright of J.L. Hintze) to calculate ID values from pooled results of quadruplicate cultures, at five drug doses, from 2-3 experiments per drug.
Cytotoxicity assays on murine lines were performed on log phase cells which were seeded at 0.5-1 x 103 in 96-well microtitre plates (Nunc). They were incubated at 37°C and 5% CO2 for 16 h and then the appropriate amount of drug or diluent was added as for the human lines. The range of doses tested was from 10-" to 10-4M. After 4 days, viable cell numbers were estimated by the method of Alley et al. (1988) and analysed by similar methods to those used for the human lines (IDm values were calculated from 12 datum points for each of 8 drug doses).
Radiation resistance
The radiation resistance was estimated previously (BechHansen et al., 1981; Pirollo et al., 1989 (1984) . Cells in exponential growth were exposed to 10-5 M VM26 (freshly prepared as a 10-2 M stock solution dissolved in dimethylsulphoxide) or I0-M novobiocin for 70 min. They were trypsinised, washed in serum-containing and then serum-free medium, then resuspended in 2 ml of serum-free RPMI 1640 to which 0.2 ml of 10% SDS, 25 ml of buffer A (1O mM Tris-HCI pH 7.5, 2% bovine serum albumin, 1% SDS) and 2.5 ml of 2.5 M KCI were added sequentially. This solution was incubated on ice for 20 min and then spun at 300g for 10 min, the supernatant discarded and the pellet resuspended twice in a wash solution buffer B (10 mM Tris-HCI pH 7.5, 100 mM KCI, 1 mM EDTA).
After recentrifugation (300 g), the pellet was suspended in 16 ml of buffer C (1O mM Tris-HCI pH 7.5, 100 mM NaCl, 1O 
Results
Both the family's fibroblast lines and the NIH-3T3 transfectants have a similar perturbation of the dose response relationship for cytoplasmic catenation activity (Figure 1) , with higher thresholds, but steeper slopes and significantly (P <0.05) elevated activity levels at high cell extract concentrations, with respect to control. Note there are different scales in the a and b panels and that the logarithmic scale is interrupted to indicate the value for no extract (0 cells). Table I gives the statistical analyses. Like all other topoisomerase assays, this assay when used with crude cell extracts cannot be assumed to be specific for topoisomerase II. We therefore confirmed that the catenation activity ( Figure 2a ) was dependent on spermidine and was reduced when exogenous ATP was omitted (Figure 2b ), characteristics of type II DNA topoisomerases. Inhibition of catenation by intercalators cannot be used to confirm that catenation activity is solely due to topoisomerase II because, as found by previous workers (Zwelling et al., 1988 ) mAMSA incompletely inhibits this activity. In our assay this may in part reflect the interference of polycations on the drug/DNA/enzyme interaction (Pommier et al., 1989) . Catenation activity was not significantly reduced by the topoisomerase I inhibitor camptothecin at 10-5 to 10-4 M (126 ± 27% and 91 ± 7% of control respectively in three experiments). Although combinations of nucleases and ligase or topoisomerase I plus nucleases could simulate catenation, the former is unlikely because spermidine and EDTA inhibit nucleases (Krasnow and Cozarelli, 1982) and the latter because it would be inhibited by camptothecin.
Nuclear catenation activity was highly variable being low or undetectable at confluence and much higher in rapidly dividing cells. It was thus not possible (since the lines have different growth rates) to make reliable comparisons between lines. In 'log phase' (albeit with different growth rates)-there was no significant difference between control nuclear extracts (NIH-3T3 and 'spouse') and murine transfectants and estimates (statistical analyses are in Table I (Davies et al., 1989) .
Nuclear and cytoplasmic extracts showed no consistent difference in relaxation of DNA supercoiling between tests and controls (Figure 3a and b) correlate with catenation activity in this assay system, nor is it dependent on ATP or spermidine (unpublished observations). Camptothecin 10-5 to 10-M, had a variable effect on the ratio of supercoiled to relaxed plasmid (data not shown) suggesting that topoisomerase I and other DNA nicking activities make a variable contribution to DNA relaxation. Ataxia telangiectasia (AT) contrasts with the Li-Fraumeni syndrome in that there is a DNA repair defect associated with a radiosensitive rather than a radioresistant phenotype (Debenham et al., 1987) . An untransformed fibroblast cell line from an AT patient (AT5BI) was therefore compared with the lines from the Li-Fraumeni syndrome family. In contrast to the family's fibroblasts, AT DNA catenation activity was reduced with respect to control, being only detectable at the highest cell extract concentration tested (3 x 105 cells per assay). Activity at this extract dose was not significantly different from the spouse's cells at a tenfold lower dose (Table I) . Relaxation of supercoiling in the AT line was not significantly different from controls (Figure 3a) .
In order to confirm the apparent perturbation of the family's DNA topoisomerase II enzyme activity, we first evaluated the response of fibroblasts from two family members, the spouse and the AT patient to a panel of cytotoxic drugs. These included those agents known to target topoisomerase I and II, and neither enzyme. Figure 4 shows the differences in responses of the fibroblasts to the panel. The tural analogue, a circa 1-2 log increase in ID25 over that seen for m-AMSA. Adriamycin and camptothecin showed no consistent difference between the family and non-family members' fibroblasts. The family's cells were more sensitive to cytosine arabinoside than the controls and less sensitive to 6-thioguanine. Similar experiments for VM26, m-AMSA, o-AMSA and cytosine arabinoside confirmed these results, albeit with less marked differences, between the raf-3T3 and NIH-3T3 cells. raf-3T3 were resistant to m-AMSA and VM26 in comparison with NIH-3T3 (Id5o 1.6 x 10-8 M versus 7.2 x 10-9 M and 3.0 x I0-9 M versus 7.8 x 10-'°M respectively). Both raf-3T3 and NIH-3T3 were at least 2 orders of magnitude less sensitive to o-AMSA than m-AMSA (ID50 1.3 x 10-6 M and 3.2 x 10-6 M respectively). As with the family lines, raf-3T3 was also relatively sensitive to cytosine arabinoside (ID50 2.3 x 10-8 M versus 6.0 x 10-7 M). The raflmyc-3T3 double transfectant did not behave like the raf-3T3 with m-AMSA, having a greater sensitivity than control (ID50 1.8 x 10-' M), but showed a similar resistance to VM26 (ID50 3.4 x 10-9 M). It also differed in its behaviour with cytosine arabinoside, being more sensitive (ID50 4.8 x 10-9 M). To substantiate further the perturbed bioactivity of the enzyme and to investigate the basis of the abnormal response to topoisomerase II inhibitors, we used the SDS/KCL precipitation method to evaluate the formation of DNA/protein complexes in response to two topoisomerase II inhibitors, novobiocin and VM26 (Figure 5a ). VM26, like VP16 usually increases the amount of precipitated complexes by trapping topoisomerase II at the stage where the enzyme is covalently linked to DNA (Osheroff, 1989) . Novobiocin, on the other hand, usually reduces the amount of complexes and this has been suggested to be due to it having a different inhibitory mechanism (stimulatory effects have sometimes been observed, but these are uncommon). In contrast to NIH-3T3 which shows this expected pattern, with more complexes in the presence of VM26 than novobiocin, all three transformants failed to show this pattern ( Figure Sb) significant change when treated with novobiocin (156 + 101% diluent control, mean ± s.e.m. three experiments). Although debated (see below), an influence of DNA topoisomerase on sublethal repair provides a potential link between ras and raf activity and radioresistance. We therefore examined the relationship between the extent of activation of topoisomerase II and the extent of radioresistence (assessed as Dq values). There was a significant positive correlation (Figure 6 ) between the percentual increase (with respect to appropriate control) in topoisomerase II activity at high cell extract concentration (mean values from Table I) and the percentual increase in Dq value. DIo values (legend to Figure 6) (Durban et al., 1983; Rottmann et al., 1987) , the activated c-raf-J gene is the obvious candidate for such a factor. Topoisomerase I activity and other DNA nicking agents, detected by relaxation of DNA supercoiling, were not disturbed and the contrasting results with the topoisomerase I inhibitor camptothecin and the topoisomerase II inhibitors in the cytotoxicity test are consistent with these enzyme assay results. The differential effect of the topoisomerase II inhibitors VP-16, VM-26 and m-AMSA on the family's cells and controls corroborates the evidence for a functional disturbance of topoisomerase II (the difference between the effects of o-AMSA and m-AMSA is consistent with their inhibitory action in the cytotoxicity assay being related to their antitopoisomerase action). Although resistant to epipodophyllotoxins, the family's cells do not exhibit classical multi-drug resistance since they are not significantly resistant to adriamycin (Ueda et al., 1987) . The discrepancy between the results for the two antimetabolities cytosine arabinoside and 6-thioguanine is obscure. Toxicity testing of the murine raftransfectant corroborated these results, including the sensitivity to cytosine arabinonside. (Durban et al., 1983; Rottmann et al., 1987) , which at first sight might be expected to potentiate drugs acting via this enyzme. However, the consequences of phosphorylation vis a vis drug/enzyme/DNA interactions are unknown. The opposing findings for AT and the family's cells (Table  II) extend not only to radiation resistance, to the radiation induced DNA synthesis delay (Paterson et al., 1985; Houldsworth & Lavin, 1980) , apparent topoisomerase II activity (at high cytoplasmic extract concentrations), but also to sensitivity to topoisomerase II targeting cytotoxics, to which the family's cells are resistant and AT cells are reportedly hypersensitive (Henner & Blazka, 1986) . This reiterates the counter-intuitive relationship between topoisomerase II activity and drug sensitivity, but, as with the family's cells, in AT topoisomerase II is probably not simply quantitatively changed but qualitatively abnormal with normal or even increased protein levels (Singh & Lavin, 1989) . Our finding of low topoisomerase II activity, which corroborates observations of Mohamed et al. (1987) and Singh et al. (1988) , contrasts with those of Smith and Makinson (1989) and Davies et al. (1989) , who found increased activity in the transformed AT5BIVA line, also in one of two untransformed AT fibroblast lines, but low enzyme content in two lymphoblastoid lines. This may reflect methodological differences in the way various assay systems detect qualitatively abnormal enzyme. The linkage between the phenomena illustrated in Table II is certainly intriguing, it extends to cell line mutants (Evans et al., 1989) and leads us to speculate that the primary lesion in the two syndromes interferes with a cellular 'machine' that is involved in regulating/producing these individual cell features.
If one allows Athat the perturbations of DNA topoisomerase II activity (both activation and inhibition) associated with observed enhancement in mutation, illegitimate recombination and the introduction of other errors may be causally related, and that an aberrant c-raf-J gene may behave like other serine-threonine kinases which have been observed to phosphorylate and hence aberrantly activate DNA topoisomerase II, this provides a readily testable hypothesis to account for the family's cells having a higher than usual mutation rate. We are currently examining phosphorylation status and error rate directly. That both activation and inhibition of the enzyme can increase error proneness, potentially reconciles the paradox of two syndromes (AT and Li-Fraumeni) with opposing findings for topoisomerase activity, sensitivity to topoisomerase inhibitors and contrasting response to radiation damage (Table II) , but each having increased mutability. (Robson et al., 1987; Elkind et al., 1988) . bRadioresistance is associated with resistance to topoisomerase II inhibitors in murine lymphoma lines (Evans et al., 1989 The presence of coexisting defects in myc and raf in the family's cells could provide a greatly increased probability for a diverse range of tumours of many types, and could reflect the complex nature of the pedigree with cancers in all four ancestral lines. The raf and myc oncogenes are known to interact synergistically in oncogenesis in experimental systems (Rapp et al., 1988) .
The influence of ras and raf transfection on radiosensitivity and our finding that both induced an identical perturbation of the topoisomerase II dose response curve, suggests that this could be associated with the radioresistant phenotype (co-ordinate findings for raf and ras may be due to ras being upstream of raf in the same signal transduction pathway (Rapp et al., 1988) ). Support for this suggested association comes from (1) the significant correlation observed between the extent of topoisomerase II activation and radiation resistance (Dq values); (2) the contrasting effects of serine/threonine kinases (raf and mos), tyrosine kinases (fes and abl) and myc on radioresistance (Pirollo et al., 1989) , given that the latter do not activate topoisomerases; (3) the association between disturbed response to topoisomerase II inhibitors and radioresistance/sensitivity observed in cell mutants (see footnote to Table II) ; and (4) the association between a radiosensitive phenotype and apparently decreased/perturbed topoisomerase II activity found in the same studies in AT.
Given the debate concerning the evidence for a role of topoisomerase II in DNA repair, speculation concerning a causal relationship between the derangement of topoisomerase II activity and radioresistance must be extremely tentative. However, controversy mostly concerns UV-induced excision repair and the use of novobiocin, an agent incorrectly assumed to be a specific inhibitor of the enzyme (Downes & Johnson, 1988) . It is premature to rule out involvement of topoisomerase in all repair processes. First, as mentioned above, the association in AT of radiosensitivity and qualitatively abnormal topoisomerase II (hypersensitive to topoisomerase II targeting cytotoxic agents (Henner & Balzka, 1986) ) is provocative. The repair defect in AT has not yet been elucidated, but misrepair (Debenham et al., 1987) rather than lack of ligation (Lehmann, 1982) of double stranded DNA breaks has been implicated. Misrepair could be a consequence of deranged topoisomerase II activity (Bae et al., 1988) . Secondly, the failure of topoisomerase II inhibitors (other than novobiocin which has pleotropic affects) to inhibit repair in some systems (Downes et al., 1987; Synder et al., 1987) , is not universal (Dressier & Robinson-Hill, 1987) .
In any case, such results do not rule out an indirect involvement of topoisomerase II related to its influence on chromatin structure, since this may not be sufficiently rapidly affected by the inhibitors in a large enough proportion of the genome to be revealed in short term experiments. Topoisomerases I and II act within and around transcriptionally active genes (Wu et al., 1988) and such genes do have an enhanced repair capacity (Bohr, 1988) . Topoisomerase may be involved in transitions of chromatin structure rather than in maintaining the 'active' chromatin configuration, since the enzyme is not found in DNAase hypersensitive, transcriptionally competent sites after transcription has subsided (Muller et al., 1987) . This notion of involvement in transitions is consistent with the observation that novobiocin has its major effect in the repair of inactive rather than active chromatin (Bohr & Hanawalt, 1986) .
The association of raf and a radioresistant phenotype is not limited to the Li-Fraumeni kindred but has been observed in head and neck cancer (Kasid et al., 1987) and with raf and amplified myc in small cell lung carcinoma (Carney et al., 1983; Rapp et al., 1988) . Since radioresistance occurs with other serine/threonine kinases and ras too, our finding may have widespread implications. If radioresistance is due to the aberrant topoisomerase this work could have direct clinical application, since this abnormality is potentially reversible. While the familial contribution to oncogenesis appears to be limited (Fraumeni, 1982) , the study of cancer families and the mechanism of their inherited susceptibility to many different forms of cancer should provide insights into some key mechanisms of oncogenesis.
